Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

Rhea-AI Summary

Werewolf Therapeutics (Nasdaq: HOWL) announced three poster presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, Nov 5-9, 2025, in National Harbor, Maryland.

Posters cover: sequential administration of IL-2 and IL-12 INDUKINE molecules (Abstract 861) on Nov 7; development of masked conditional T cell engagers (Abstract 964) on Nov 8; and pharmacokinetics of IL-2 INDUKINE prodrug WTX-124 (Abstract 862) on Nov 8. All presentations in Poster Hall (Exhibit Halls A and B1).

News Market Reaction

+6.77%

8 alerts

+6.77% News Effect

+15.9% Peak in 6 hr 31 min

+$6M Valuation Impact

$96M Market Cap

0.6x Rel. Volume

On the day this news was published, HOWL gained 6.77%, reflecting a notable positive market reaction. Argus tracked a peak move of +15.9% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $6M to the company's valuation, bringing the market cap to $96M at that time.

Data tracked by StockTitan Argus on the day of publication.

WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that three posters will be presented at the upcoming Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting, taking place November 5-9, 2025, in National Harbor, Maryland.

Details for the poster presentations are as follows:

Title: Sequential administration of WTX-124 and mWTX-330, IL-2 and IL-12 INDUKINE™ molecules, enhanced antitumor activity in mice bearing poorly immunogenic EMT6 tumors without systemic toxicity
Abstract Number: 861
Session Date and Time: Nov. 7, 2025; 12:15-1:45, 5:10-6:35 p.m.
Location: Poster Hall (Exhibit Halls A and B1)

Title: Development of conditional T cell engagers (INDUCER™ molecules) with a highly effective masking approach to reduce dose-limiting cytokine release and off-target peripheral toxicity
Abstract Number: 964
Session Date and Time: Nov. 8, 2025; 12:15-1:45, 5:10-6:35 p.m.
Location: Poster Hall (Exhibit Halls A and B1)

Title: Pharmacokinetic insight into the IL-2 INDUKINE prodrug WTX-124: real-time assessment of tumor-specific activation and immune modulation
Abstract Number: 862
Session Date and Time: Nov. 8, 2025; 12:15-1:45, 5:10- 6:35 p.m.
Location: Poster Hall (Exhibit Halls A and B1)

About Werewolf Therapeutics

Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR^® platform to design conditionally activated INDUKINE™ and INDUCER™ molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple solid tumor types as a single agent. Werewolf is leveraging positive data from its INDUKINE molecules to advance the development of INDUCER molecules. Werewolf’s first INDUCER development candidate, WTX-1011, targets STEAP1 for prostate cancer. To learn more visit www.werewolftx.com.

WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™, INDUCER™, and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.

Investor Contact:
Dan Ferry
LifeSci Advisors
617.430.7576
daniel@lifesciadvisors.com

Media Contact:
Amanda Sellers
Deerfield Group
301.332.5574
amanda.sellers@deerfieldgroup.com

Company Contact:
Timothy Trost
Chief Financial Officer
Werewolf Therapeutics
ttrost@werewolftx.com

FAQ

When will Werewolf Therapeutics (HOWL) present at SITC 2025?

Werewolf will present posters on Nov 7 and Nov 8, 2025 during SITC 40th Annual Meeting.

What topics will HOWL cover in its SITC 2025 posters?

Topics include WTX-124 pharmacokinetics, sequential IL-2/IL-12 INDUKINE antitumor activity, and masked conditional T cell engagers.

Where are Werewolf’s posters located at SITC 2025?

All three posters are in the Poster Hall (Exhibit Halls A and B1) at National Harbor.

What are the abstract numbers for Werewolf’s SITC 2025 posters?

Abstract numbers are 861 (WTX-124 + mWTX-330), 862 (WTX-124 PK), and 964 (conditional T cell engagers).

Does the press release report clinical or financial results for HOWL?

No. The release announces poster presentations and does not include clinical readouts or financial data.

How can investors view Werewolf’s SITC 2025 presentations for HOWL?

Attend SITC in person at National Harbor on Nov 7–8, 2025 in Poster Hall; check Werewolf investor relations for any published abstracts or slides.